Institutional members access full text with Ovid®

Share this article on:

Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study

Novick, Diegoa; Haro, Josep Mariab; Suarez, Davidc; Marques-Teixeira, Joãod; Naber, Dietere

International Clinical Psychopharmacology: July 2008 - Volume 23 - Issue 4 - pp 203-208
doi: 10.1097/YIC.0b013e3282ff5fed
Original Articles

Data from the European Schizophrenia Outpatient Health Outcomes, a 3-year, prospective, observational study of health outcomes associated with antipsychotic treatment in outpatients with schizophrenia (n=10 972 enrolled), were used to assess the impact of the first switching of antipsychotic medications, with a focus on olanzapine, on clinical status and tolerability outcomes. Patients were defined as those who (1) started olanzapine at baseline and changed treatment; (2) started another antipsychotic at baseline and changed to olanzapine; and (3) changed from and to a non-olanzapine antipsychotic. A logistic regression model was used to analyse the impact of switching on treatment response and tolerability. Patients switching from olanzapine were less likely to respond than patients switching to olanzapine (OR: 0.59; 95% CI: 0.40, 0.87). Patients who switched from olanzapine and those who switched neither from nor to olanzapine were more likely to have extrapyramidal symptoms (OR: 3.79; 95% CI: 2.02, 7.10 and OR: 2.18; 95% CI: 1.23, 3.86, respectively) and loss of libido (OR: 1.89; 95% CI: 1.21, 2.96 and OR: 1.56; 95% CI: 1.04, 2.35, respectively) compared with patients who switched from another antipsychotic to olanzapine. Patients who switched to olanzapine experienced a higher weight gain. In conclusion, among patients switching antipsychotic medication, those who switched to olanzapine had better long-term outcomes.

aEli Lilly & Company, Windlesham, Surrey, UK

bSaint John of God Research and Teaching Foundation, Santa Rosa, 39-57, Esplugues de Llobregat, Barcelona

cSaint John of God Research and Teaching Foundation, Mental Health Services, Dr Antoni Pujades 42, Sant Boi de Llobregat, Barcelona, Spain

dUniversity of Porto, Porto, Portugal

eUniversity Medical Centre Hamburg, Eppendorf, Department of Psychiatry and Psychotherapy, Martinistrasse 52, Hamburg, Germany

Correspondence to Diego Novick, Lilly Research Centre, Eli Lilly & Company, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, UK

Tel: +44 1276 483832; fax: +44 1276 483192;

e-mail: novick_diego@lilly.com

Received 9 September 2007 Accepted 3 March 2008

© 2008 Lippincott Williams & Wilkins, Inc.